Stevens Capital Management LP purchased a new stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 16,505 shares of the biotechnology company’s stock, valued at approximately $1,734,000.
Other large investors have also recently modified their holdings of the company. FMR LLC grew its stake in bluebird bio by 0.6% in the 1st quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock worth $556,918,000 after acquiring an additional 37,742 shares in the last quarter. State of Wisconsin Investment Board bought a new position in bluebird bio in the 2nd quarter worth about $3,257,000. Winfield Associates Inc. grew its stake in bluebird bio by 6.1% in the 2nd quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock worth $296,000 after acquiring an additional 162 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new position in bluebird bio in the 2nd quarter worth about $1,061,000. Finally, Alliancebernstein L.P. grew its stake in bluebird bio by 50.1% in the 1st quarter. Alliancebernstein L.P. now owns 85,860 shares of the biotechnology company’s stock worth $7,805,000 after acquiring an additional 28,640 shares in the last quarter.
In other bluebird bio news, insider David Davidson sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $92.37, for a total transaction of $277,110.00. Following the completion of the transaction, the insider now owns 18,977 shares in the company, valued at approximately $1,752,905.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Maraganore sold 18,868 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $131.21, for a total transaction of $2,475,670.28. Following the transaction, the director now owns 24,711 shares of the company’s stock, valued at approximately $3,242,330.31. The disclosure for this sale can be found here. Insiders have sold a total of 165,616 shares of company stock valued at $19,447,660 in the last quarter. 3.90% of the stock is currently owned by company insiders.
A number of equities analysts have commented on BLUE shares. Cowen and Company restated an “outperform” rating on shares of bluebird bio in a research note on Thursday, August 31st. Wedbush restated an “outperform” rating and issued a $135.00 target price (up from $121.00) on shares of bluebird bio in a research note on Friday, September 1st. Cantor Fitzgerald set a $37.00 target price on shares of bluebird bio and gave the stock a “sell” rating in a research note on Monday, June 5th. Wells Fargo & Company restated an “outperform” rating and issued a $158.00 target price (up from $134.00) on shares of bluebird bio in a research note on Tuesday, September 5th. Finally, BTIG Research downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and upped their target price for the stock from $37.05 to $108.25 in a research note on Friday, June 30th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $107.86.
TRADEMARK VIOLATION NOTICE: “16,505 Shares in bluebird bio, Inc. (BLUE) Acquired by Stevens Capital Management LP” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2017/09/22/16505-shares-in-bluebird-bio-inc-blue-acquired-by-stevens-capital-management-lp.html.
Shares of bluebird bio, Inc. (BLUE) opened at 127.85 on Friday. The company’s 50-day moving average is $108.37 and its 200-day moving average is $97.10. The stock’s market cap is $5.83 billion. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $136.85.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same quarter last year, the firm earned ($1.59) EPS. The company’s revenue was up 977.4% on a year-over-year basis. Equities analysts anticipate that bluebird bio, Inc. will post ($6.84) EPS for the current year.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.